Offer Undervalues PharMerica and Provides No Certainty of Closing

LOUISVILLE, Ky.–(CRWENewswire)– PharMerica Corporation (NYSE:PMC), a national provider of institutional pharmacy and hospital pharmacy management services, today announced that its Board of Directors, after careful consideration with its independent financial and outside legal advisors, voted unanimously to reject the unsolicited tender offer made by Omnicare (NYSE:OCR) to acquire PharMerica for $15.00 per share in cash. The Board determined that the offer undervalues PharMerica and is not in the best interests of PharMerica’s stockholders. In addition to undervaluing PharMerica and its future prospects, the Board believes the offer is illusory because it is subject to significant regulatory and other uncertainty. The Board unanimously recommends that PharMerica stockholders reject Omnicare’s offer and not tender their shares to Omnicare.

The Board noted that the value offered by Omnicare is unchanged from the unsolicited proposal it first made privately on July 19, 2011 and subsequently made public on August 23, 2011.

“The PharMerica Board of Directors is unanimous in its well-informed belief that Omnicare’s offer is lacking in both price and certainty of closing,” said Gregory S. Weishar, PharMerica Chief Executive Officer. “The PharMerica Board believes that the continued pursuit of our strategic plan will yield greater value for PharMerica stockholders than the Omnicare offer. Omnicare also remains stubbornly unwilling to provide any assurance to PharMerica stockholders that it will be in a position to complete a transaction in a timely manner at any price — and despite its professed confidence in attaining regulatory approval refuses to take on the contractual risk of closing. The PharMerica Board strongly urges stockholders to reject Omnicare’s deficient offer and not to tender their shares to Omnicare.”

The Board’s reasons for rejecting Omnicare’s unsolicited offer include its beliefs that:

* Omnicare’s unsolicited offer undervalues PharMerica and its future prospects.

- The Board has confidence in PharMerica’s strategic plan, which is focused on client retention, customer service, and improving its core pharmacy services and acquisitions, and believes that execution of the plan will deliver greater value to its stockholders than would be obtained under the current Omnicare offer.

- PharMerica recently completed acquisitions of Ark Pharmacy and ChemRx, and is just beginning to realize the significant value creation potential of these acquisitions.

- Omnicare’s offer fails to appropriately compensate PharMerica stockholders for the synergies Omnicare would derive from combining the largest and second largest players in the institutional pharmacy market.

- PharMerica is the second largest institutional pharmacy services company in the United States based on revenues and is the largest remaining independent public company in the institutional pharmacy market. Omnicare’s offer does not reflect the unique strategic value of PharMerica to Omnicare.

* The offer is illusory because it is subject to significant regulatory and other uncertainty.

- A transaction with Omnicare would likely undergo a lengthy regulatory review process with no assurance of Omnicare’s ability to complete a transaction on a timely basis or at all. Antitrust clearance to combine competitors with #1 and #2 market share in institutional pharmacy is likely to be difficult to achieve and involve lengthy administrative and court proceedings.

- Even if the antitrust issues could eventually be resolved in a satisfactory manner, the offer introduces unacceptably high risk to PharMerica stockholders and would have a material adverse effect on PharMerica’s ability to attract and retain key personnel, employees and customers.

- In light of recent actions by the Department of Justice, including its decision to sue to stop AT&T’s proposed acquisition of T-Mobile USA, the PharMerica Board believes the current environment is not conducive to obtaining timely regulatory approval for a combination with Omnicare.

- While Omnicare has publicly expressed its confidence in a timely regulatory approval, it has been unwilling to take on the contractual risk of closing.

- Given the regulatory uncertainty and the significant conditionality of Omnicare’s offer, there is considerable uncertainty regarding the offer and the timing of PharMerica stockholders receiving the $15.00 that Omnicare claims to be offering.

- Because Omnicare is a competitor of PharMerica, there are also serious competitive risks to PharMerica and its business in providing non-public information to Omnicare if the transaction is not completed due to antitrust, regulatory, or other issues.

* The timing of Omnicare’s unsolicited offer is opportunistic and disadvantageous to PharMerica’s stockholders.

- The offer is being made at a time when Omnicare can take advantage of PharMerica’s lower stock valuation resulting from regulatory uncertainty in the healthcare industry due to new healthcare legislation.

- The offer is being made in advance of the wave of branded to generic drug conversions that will happen in 2012 and beyond, which is expected to be beneficial to PharMerica’s operating results.

- After its unsolicited proposal was rejected privately in July as being inadequate, Omnicare publicized it during a period of market volatility in order to claim an inflated premium.

The full basis for the Board’s recommendation is set forth in PharMerica’s Schedule 14D-9 filed today with the Securities and Exchange Commissions.

Deutsche Bank Securities Inc. is acting as financial advisor and Holland & Knight LLP is acting as legal advisor to PharMerica.

About PharMerica

PharMerica Corporation is a leading institutional pharmacy services company servicing healthcare facilities in the United States. PharMerica operates institutional pharmacies in 44 states. PharMerica’s customers are institutional healthcare providers, such as nursing centers, assisted living facilities, hospitals and other long-term care providers. The Company also provides pharmacy management services to long-term care hospitals.

Additional Information

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. In response to the tender offer, PharMerica will file a solicitation/recommendation statement on Schedule 14D-9 with the U.S. Securities and Exchange Commission (“SEC”). INVESTORS AND STOCKHOLDERS OF PHARMERICA ARE URGED TO READ THESE AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders may obtain free copies of these documents and other documents filed with the SEC by PharMerica through the web site maintained by the SEC at http://www.sec.gov. In addition, documents filed with the SEC by PharMerica may be obtained free of charge by contacting PharMerica’s information agent, Georgeson Inc., at (866) 647-8872.

Forward Looking Statements

This press release contains “forward-looking statements,” including, but not limited to, statements regarding PharMerica’s strategic plan, prospects, value of the Omnicare offer, regulatory uncertainty, and impact of the conversion of branded to generic drug conversions. These forward-looking statements are based upon information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause the Company’s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These factors and risks include, but are not limited to, the outcome of, or developments concerning, the Offer; other potential commercial or business combination proposals that have or may be received in the future; the outcome of any litigation related to the Offer or any other offer or proposal and the Board’s recommendation to the stockholders concerning the Offer or any other offer or proposal; PharMerica’s access to capital, credit ratings, indebtedness, and ability to raise additional financings and operate under the terms of PharMerica’s debt obligations; the effects of adverse economic trends or intense competition in the markets in which PharMerica operates; the effects of retaining existing customers and service contracts and PharMerica’s ability to attract new customers for growth of PharMerica’s business; PharMerica’s ability to successfully pursue PharMerica’s development and acquisition activities and successfully integrate new operations and systems, including the realization of anticipated revenues, economies of scale, cost savings, and productivity gains associated with such operations; PharMerica’s ability to control costs, particularly labor and employee benefit costs, rising pharmaceutical costs, and regulatory compliance costs; the effects of healthcare reform and government regulations, including, interpretation of regulations and changes in the nature and enforcement of regulations governing the healthcare and institutional pharmacy services industries; changes in the reimbursement rates or methods of payment from Medicare and Medicaid and other third party payers to both PharMerica and its customers; PharMerica’s ability to anticipate a shift in demand for generic drug equivalents and the impact on the financial results including the negative impact on brand drug rebates; and other factors, risks and uncertainties referenced in PharMerica’s filings with the SEC, including the “Risk Factors” set forth in PharMerica’s Annual Report on Form 10-K for the year ended December 31, 2010. You are cautioned not to place undue reliance on any forward-looking statements, all of which speak only as of the date of this press release. Except as required by law, we undertake no obligation to publicly update or release any revisions to these forward-looking statements to reflect any events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. All written and oral forward-looking statements attributable to us or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this press release and in the Risk Factors section set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC and in other reports filed with the SEC by the Company.

Contact:

PharMerica Corporation
Michael J. Culotta, 502-627-7475
Executive Vice President and Chief Financial Officer
or
Sard Verbinnen & Co
David Reno/Meghan Stafford, 212-687-8080

Source: PharMerica Corporation

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (OTCBB:CRWE) announced that its subsidiary company, Crown Tele Services Inc. is still moving forward after dissolving its joint venture with Communication Expert Corporation and will gradually start rolling out its internet based voice and video service IP-PBX solutions next year.

The cornerstone of Crown Tele Services Inc. strategy is to meet the highest standards when it comes to delivering VoIP (Voice over Internet Protocol) communication solutions specifically designed to meet the market needs.

Hosted IP-PBX lets you share a number of incoming phone lines among a larger number of extensions, so it’s not necessary to pay for a separate line for every office employee or workstation, which saves money. But the implementation and ongoing maintenance of an VOIP PBX system requires a type of expertise that your IT staff may not have. And if you go with a commercial product, the up-front costs for the hardware and software may be high.

Crown Equity Holdings Inc., together with its digital network, currently provides electronic media services specializing in online publishing and Web sites, which bring together targeted audiences and advertisers that want to reach them. Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness.

Douglas Lake Minerals (OTCBB:DLKM) is pleased to announce that it has filed a Canadian National Instrument 43-101 Standards for Disclosure of Mineral Projects (”NI 43-101) Technical Report (the “Technical Report”) for its Handeni Project. Douglas Lake’s 100% owned Handeni Project consists of four prospecting licenses covering approximately 800 square kilometers in the newly developing goldfields of Eastern Tanzania. Douglas Lake filed the Technical Report with the British Columbia Securities Commission via the System for Electronic Document Analysis and Retrieval (SEDAR).

The Technical Report was prepared by Dr. Reyno Scheepers, Ph.D., Pr.Sci.Nat., a South African based consulting geologist and a director of the Company who fulfills the requirements to be a ‘Qualified Person’ for the purposes of NI 43-101.

The Technical Report details the results of exploration activities conducted by IPP Resources, the previous holding company of the area. Extensive geophysical and geologic work was conducted over several field seasons from 2008. The work included prospecting, rock and soil sampling, and a ground magnetic survey. All geochemical analytical work was conducted by internationally accredited labs, SGS Laboratories and/or Humac Laboratories in Mwanza, Tanzania.

The exploration also included a fixed-wing aeromagnetic and radiometric survey. The survey and interpretation was conducted according to internationally accepted standards by the Council for Geoscience, South Africa. The Technical Report identified and selected a total of 12 priority gold targets which are recommended for follow up work.

“The scale of work covered by the Technical Report has significantly advanced Douglas Lake’s Handeni Project,” Harp Sangha, Chief Executive Officer comments, “We now have a number of very exciting gold targets which we are a priority for us to follow up with further exploration in 2011.”

Douglas Lake is an emerging mineral exploration company focused on exploring and developing mining opportunities in Tanzania.

Eaton Vance Tax-Managed Global (NYSE:EXG) announced the quarterly distributions declared on the common shares of two of its closed-end equity funds (the “Funds”). The record date for the distributions is February 18, 2011, and the payable date is February 28, 2011. The ex-date is February 16, 2011.

Eaton Vance Tax-Managed Global Diversified Equity Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund’s primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation.

Nuveen Dividend Advantage Municipal Fund (NYSE:NAD) announced that 112 Nuveen closed-end funds had declared regular monthly distributions. These funds represent a broad range of tax-exempt, taxable fixed and floating rate income investment strategies for investors seeking to build sophisticated and diversified long-term investment portfolios for cash flow.

Nuveen Dividend Advantage Municipal Fund is a closed-ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is managed by Nuveen Asset Management. It invests in the fixed income markets of the United States. The fund invests in undervalued municipal securities and other related investments, the income from which is exempt from regular federal income taxes.

PharMerica Corporation (NYSE:PMC) announced that it has acquired substantially all the assets of Lone Star Pharmacy based in Garland, Texas. Lone Star Pharmacy is a full service pharmacy to long-term care and assisted living facilities primarily in Dallas and Houston. The transaction closed on December 31, 2010, and was financed with existing cash and borrowings under the Company’s revolving line of credit. The Company expects the acquisition to be accretive to earnings in 2011.

PharMerica Corporation operates as an institutional pharmacy services company in the United States. It offers services to healthcare facilities and provides management pharmacy services to hospitals. The company purchases, repackages, and dispenses prescription and non-prescription pharmaceuticals in accordance with physician orders and delivers such medication to healthcare facilities for administration to individual patients and residents.

**********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (OTCBB:CRWE) together with its digital network, currently provides electronic media services specializing in online publishing and Web sites, which bring together targeted audiences and advertisers that want to reach them.

CRWE’s mission is to profitably disseminate a variety of information as a worldwide online media publisher in an environment that has a positive effect.

A successful business campaign takes careful planning, expert professional advice, and a range of resources. With our online marketing expertise, we offer a complete line of services to help your company achieve its goals. At Crown Equity Holdings Inc. you’ll find creative advertising service at competitive rates.

Advertise your business adjacent with our digital network content to our targeted audience, which are educated high income individuals. Since we are associated with many sites, your banner and/or information could appear on other sites as well.

Our Information Technology services includes Website designing, Graphics, Web Hosting, Domain names, as well as well as domain transferring, management and maintenance of sites. Our department has experience in maintaining, monitoring and installing in a LAMP environment, as well as extensive experience in HTML, AJAX, JavaScript, CSS, PHP, MYSQL and other web technologies.

**********************************************

PharMerica Corporation (NYSE:PMC) announced on Dec 15, 2010 that Thomas P. Mac Mahon, the Company’s non-executive Chairman, is transitioning PharMerica’s Chairmanship to fellow Board member Geoffrey Meyers. Mr. Mac Mahon will remain a member of the PharMerica Board of Directors and a member of the Compensation Committee. Mr. Meyers will become non-executive Chairman on January 1, 2011. Mr. Meyers joined the PharMerica Board in 2009 and is a member of the Company’s Nominating and Governance Committee. He is a recognized leader in the long-term care industry.

PharMerica Corporation operates as an institutional pharmacy services company in the United States. It offers services to healthcare facilities and provides management pharmacy services to hospitals. The company purchases, repackages, and dispenses prescription and non-prescription pharmaceuticals in accordance with physician orders and delivers such medication to healthcare facilities for administration to individual patients and residents.

**********************************************

PIMCO New York Municipal Income Fund III (NYSE:PYN) announced that they have declared dividends on the Funds’ common shares: PIMCO New York Municipal Income Fund III. The dividends will be payable on December 29, 2010 to shareholders of record on December 13, 2010, with an ex-dividend date of December 9, 2010.

PIMCO New York Municipal Income Fund III (the Fund) is a non-diversified, closed-end management investment company. The Fund invests substantially all of its assets in municipal bonds, which pay interest that is exempt from federal, New York State and New York income taxes. The Fund would generally seek to avoid investing in bonds generating interest income, which could subject individuals to alternative minimum tax.

**********************************************

Flaherty & Crumrine Preferred Income Opportunity Fund Incorporated (NYSE:PFO) The Boards of Directors of Flaherty & Crumrine Preferred Income Fund Incorporated (NYSE:PFD) and Flaherty & Crumrine Preferred Income Opportunity Fund Incorporated (NYSE:PFO) approved new regular monthly dividend amounts and declared a special year-end dividend to be paid in December. The new regular monthly dividend rate for PFD will be $0.09 per share, which equates to an annual dividend of $1.08 per share. This new monthly dividend represents an increase of approximately 1.1% over the prior monthly dividend. In addition, shareholders will receive a special year-end dividend from net investment income of $0.03 per share.

Flaherty & Crumrine Preferred Income Opportunity Fund Incorporated is a close-ended equity mutual fund launched and managed by Flaherty & Crumrine Incorporated. The fund invests in the public equity markets of the United States. It invests in stocks of companies operating in the finance and utility sector. The fund primarily invests in preferred stocks. It typically invests in securities with an average credit rating of BBB- by Standard & Poor’s Corporation and Baa3 by Moody’s Investors Services, Inc.

************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Delivery Technology Solutions, Inc. (Pinksheets:DTSL), the leader in delivery management technology, has completed participation at one of the largest restaurant franchisee conventions, held July 22-25, 2010. Its UDS division attended the convention by invitation of the leading franchisor, and was able to showcase its large corporate catering and event management delivery technology platform to many of the thousands of convention attendees, and a range of other potential partners in the industry and associated industries.

“This was our first opportunity to interact face-to-face on a large scale with franchisees from all across American, Canadian, European, Middle Eastern and Asian markets,” said Ryan Coblin, CEO. “We could shake their hands, explain the opportunities our solutions offer, answer their questions and sign them up for follow-up contacts.”

Over the three-day event the company was successful in signing up franchisees that own thousands of locations, and multiple-territory development agents who represent thousands more. These signed prospects will be contacted by the franchisor and UDS to offer them optional programs to expand their customer base, increase sales and build new profits for their restaurants. Qualified franchisees are enrolled in the optional programs, and then UDS proprietary software is implemented at their unit, so orders may be received from the UDS Call Center and Online Ordering technology.

“As exciting as it was to meet the franchisees and development agents,” Mr. Coblin commented, “We also connected with old and new friends in the vendor community, representing some of the most famous brands in the industry, and other Fortune 500 companies, to open and further discussions toward cooperative partnerships to develop greater opportunities within the franchise population.”

**************************************************************

Pharmasset, Inc. (Nasdaq: VRUS) has received fast track designation from the U.S. Food and Drug Administration (FDA) for PSI-7977 for the treatment of chronic hepatitis C virus (HCV) infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1. Pharmasset expects to initiate a 12-week Phase 2b study of PSI-7977 in the fourth quarter of 2010.

Under the FDA Modernization Act of 1997, fast track designation may facilitate the development and expedite the review of a drug candidate that is intended for the treatment of a serious and life-threatening condition and demonstrates the potential to address an unmet medical need for such a condition. PSI-7977 was granted the fast track designation primarily due to the need for HCV treatments with novel mechanisms of action, oral administration, different resistance profiles and improved safety and efficacy over the existing standard of care for both treatment-naive and treatment-experienced patients.

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset’s primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have four clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys(R) plus Copegus(R) and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog that has recently completed 28 days of dosing in a Phase 2a study, and PSI-938, an unpartnered guanosine nucleotide analog in a Phase 1 study. We also have in our pipeline an additional purine nucleotide analog, PSI-661, in advanced preclinical development. Racivir, for the treatment of HIV, has completed a Phase 2 clinical study.

**************************************************************

PharMerica Corporation (NYSE: PMC), an industry-leading pharmaceutical services company serving residents in long-term facilities and settings, has reached a “stalking horse” asset purchase agreement to buy substantially all of the assets of Chem Rx Corporation.

Partnering with Chem Rx will allow PharMerica to expand into New York and New Jersey, where it currently does not have a presence. Chem Rx will continue to maintain normal business operations throughout this process and thereafter.

Per the terms of the agreement, Chem Rx’s founder Jerry Silva and management team, including Steve Silva, Gary Jacobs, Evan Selzer, Paula Agoglia, Jody Silva-Falk, Shelly Evans, Michael Segal and Leora Tilocca will continue to be responsible for the day-to-day operations of Chem Rx. The company will also continue to operate under the Chem Rx name. The sale, conducted pursuant to Section 363 of the U.S. Bankruptcy Code, will significantly eliminate the company’s debt.

Like Chem Rx, PharMerica is dedicated to providing quality customer service and innovative pharmacy solutions to institutional customers and patients in long-term care settings. A leader in U.S. industrial pharmaceutical services, PharMerica operates 90 institutional pharmacies in 41 states that serve more than 300,000 licensed beds for patients of long-term care facilities. PharMerica has approximately 6,000 employees nationwide.

**************************************************************

PHC, Inc., d/b/a Pioneer Behavioral Health (NYSE Amex: PHC), a leading provider of inpatient and outpatient behavioral health services, reported financial results for the Company’s 2010 fourth fiscal quarter and full fiscal year ended June 30, 2010. The results exclude the operations of the Company’s research division, Pivotal Research Centers, Inc. (Pivotal), which was sold during the 2009 third fiscal quarter and was accounted for as a discontinued operation in fiscal 2009.

PHC, Inc., d/b/a Pioneer Behavioral Health, is a national healthcare company providing behavioral health services in five states, including substance abuse treatment facilities in Utah and Virginia, and inpatient and outpatient psychiatric facilities in Michigan, Pennsylvania, and Nevada. The Company also offers internet and telephonic-based referral services that includes employee assistance programs and critical incident services. Contracted services with government agencies, national insurance companies, and major transportation and gaming companies cover more than one million individuals. Pioneer helps people gain and maintain physical, spiritual and emotional health through delivering the highest quality, most culturally responsive and compassionate behavioral health care programs and services

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty-five thousand dollars in cash from a third party (Ceiba Network/PenStox) for (30) days of advertising for Delivery Technology Solutions, Inc. (DTSL.PK)

________

Proteonomix, Inc. (PROT) Plans European Investor Road Show

-Michael Cohen, Chairman and CEO, to Visit Several European Cities to Discuss Company’s Growth Plan and Future Outlook With Investors

PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced last week that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (”XGen”), a Nevis Island limited liability company.

For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.

“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD).

http://www.proteonomix.com/

________

Computer Programs and Systems, Inc. (NASDAQ:CPSI)

CPSI, a leading provider of healthcare information solutions, recently announced results for the second quarter and six months ended June 30, 2010.

The Company also announced that its Board of Directors has declared a regular quarterly cash dividend of $0.36 (thirty-six cents) per share, payable on August 27, 2010, to stockholders of record as of the close of business on August 12, 2010.

Total revenues for the second quarter ended June 30, 2010, increased 22.3% to $37.7 million, compared with total revenues of $30.8 million for the prior-year period. Net income for the quarter ended June 30, 2010, increased 20.4% to $4.3 million, or $0.39 per diluted share, compared with $3.5 million, or $0.32 per diluted share, for the quarter ended June 30, 2009. Cash provided by operations for the second quarter of 2010 was $2.8 million, compared with $3.7 million of cash provided by operations for the prior-year period.

http://www.cpsinet.com

________

PharMerica Corporation Announces Share Repurchase Program

PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, recently announced that its Board of Directors has authorized the repurchase of up to $25 million of the Company’s common stock. The share repurchases will be made in the open market through unsolicited or solicited privately negotiated transactions, or in such other appropriate manner, and will be funded from available cash.

The amount and timing of the repurchases will be determined by the Company’s management and will depend on a variety of factors including price, corporate and regulatory requirements, capital availability and other market conditions. Common stock acquired through the share repurchase program will be held as treasury shares and may be used for general corporate purposes, including reissuances in connection with acquisitions, employee stock option exercises or other employee stock plans.

The share repurchase program does not have an expiration date and may be limited, terminated or extended at any time without prior notice.

PharMerica Corporation is a leading institutional pharmacy services company servicing healthcare facilities in the United States. As of June 30, 2010, PharMerica operated 90 institutional pharmacies in 41 states. PharMerica’s customers are institutional healthcare providers, such as nursing centers, assisted living facilities, hospitals and other long-term care providers. The Company also provides pharmacy management services to long-term care hospitals.

www.pharmerica.com

________

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB).